TOI · The Oncology Institute, Inc.

Current Thesis

The Oncology Institute is a value-based community-oncology services operator capitated and delegated-risk contracts with Medicare Advantage payers, plus a dispensary/pharmacy segment inflecting to its first full year of profitability after years of fee-for-service losses. Q1'26 (reported 2026-05-07) put revenue at $147.4M, +41% YoY, beating the $143.2M consensus, with the net loss collapsing to $2.5M from $19.6M a year earlier and adjusted EBITDA at $(2.4)M versus $(5.1)M. Management affirmed FY26 revenue of $630–650M and an adjusted-EBITDA range of $0–9M the first profitable year as a public company. The stock has tripled off its $2.02 fifty-two-week low to ~$4.87 (2026-06-05) and now sits just under a fresh 52-week high of $5.17. The fundamental story is accelerating; the entry is not. Price is pinned to the high of its range with no hard catalyst inside 30 days, which makes a fresh long at these levels a chase. The redeeming detail is a 10% owner who keeps buying open-market into strength.

Bull Case

• Profitability inflection landing on schedule. FY26 adjusted-EBITDA guide of $0–9M (affirmed 2026-05-07) marks the first profitable year as a public company; Q1'26 net loss fell to $2.5M from $19.6M YoY. The turnaround is showing in the P&L, not just the slide deck.
• Florida capitation now profitable. Delegated-risk relationships in Florida have matured to profitability; ~$150M of the $630–650M FY26 revenue is capitation. The Elevance delegated partnership (~70,000 lives) is guided to more than double across the state in 2026, and Humana/CarePlus added ~22,000 South Florida MA lives (disclosed with the 2026-01-12 outlook, reaffirmed on the Q1 call).
• Concrete forward ramp. Management plans to extend Florida partnerships into 11 additional counties in Q3, covering ~200,000 Medicare Advantage lives visible operating leverage building toward 2027, when full delegated-contract economics are guided to land.
• Top-line acceleration. Q1'26 revenue +41% YoY on capitated growth plus record dispensary performance; the FY26 midpoint implies ~+28% growth on a ~$546M trailing base.
• Insider conviction, repeated. 10% owner Jorey Chernett bought 12,000 shares at $4.75 on 2026-06-05, on top of an earlier 30,000-share open-market buy. A repeat insider paying up into a rising tape is an unambiguous tell.
• Sell-side onside with room above. Four analysts, consensus Strong Buy, average price target ~$7.00 across a $5–8 range (B. Riley, Needham, BTIG). Spot trades below even the low target.
• Trend and liquidity both improving. Price holds above the rising 20-, 50- and 200-day averages; six-month return ~+56%. Average volume has expanded to ~4.2M shares (~$20M/day) from ~1.85M, so the advance is no longer wholly dependent on a thin tape.

Bear Case

• Buying the high of the range. A fresh long near $4.87–5.17 is an entry at the 52-week high after a triple, with price well above the 200-day. No new business announcement justifies a break to new highs from here; the last leg has run on squeeze and insider flow rather than a fundamental print.
• No hard catalyst for ~9 weeks. Q2'26 earnings land ~early-to-mid August. Nothing scheduled inside 30 days forces the move higher, and a short squeeze with no fundamental refuel can bleed back toward support.
• Thin profitability cushion. The adjusted-EBITDA guide starts at $0. One delegated contract that ramps slower than planned, or an MA reimbursement-rate squeeze, flips the headline from "first profitable year" back to "still losing money." Gross margin is only ~14%.
• Balance-sheet thinness. Cash was $30.3M at 2026-03-31 against a model still near breakeven; a capital raise into a higher share price would be rational for management and dilutive for holders.
• Cybersecurity tail. The November 2025 incident got a 2026-05-22 follow-up confirming a software vendor had unauthorized access to information. Healthcare-data exposure carries remediation cost and HIPAA-related tail risk that remains unquantified.
• Squeeze cuts both ways. An 11.3% short float and ~3.5-day cover ratio amplify upside on good news and downside on disappointment; micro-cap liquidity gaps in both directions.

Setup & Price Structure

• Spot ~$4.87 (2026-06-05), ~5% under the fresh 52-week high of $5.17; 52-week range $2.015–$5.17.
• Price above the rising 20-day (~$4.40), 50-day (~$3.90) and 200-day (~$3.55); +33% YTD, ~+56% over six months. RSI(14) sat near 65 a week ago strong, not yet a blow-off.
• Float 57.65M of 99.97M shares out; short interest 11.31% of float, ~3.5 days to cover. Market cap ~$487M.
• Liquidity has improved to ~4.2M average shares (~$20M/day) from ~1.85M, which dampens but does not remove the pure-illiquidity whipsaw risk at this cap.
• The clean structure would be a pullback that holds the $4.00–4.40 shelf (prior breakout base plus the rising 20-day) and prints a higher low, or a daily close and hold above $5.17 on expanding volume. Buying mid-range at the high after a vertical move is the lower-quality version of the same idea.

Catalyst Calendar (next 30 days)

• No scheduled hard catalyst inside the 2026-06-07 → 2026-07-07 window.
• ~2026-07 (Q3 start, est.): Florida delegated-capitation expansion into 11 additional counties / ~200,000 MA lives begins to ramp an operational ramp rather than a single dated event, landing just at or beyond the 30-day edge.
• Ongoing, unscheduled: Form 4 insider activity (Chernett has now bought twice; watch for further open-market adds).
• ~early-to-mid August 2026 (est., outside window): Q2'26 print the next binary test of the FY26 adjusted-EBITDA guide and capitation-revenue trajectory. Avoid fresh entries within three trading days of the confirmed date.

What Would Change Our Mind

• Bullish confirmation: a daily close and hold above $5.17 on above-average volume (clean breakout to new highs); a new payer or county-expansion announcement ahead of Q3; a third sizable insider open-market buy.
• Thesis break: a daily close below $4.00 failed breakout, loses the rising 20-day, fills the gap, trend broken. Fundamentally, a Q2'26 print (~August) that cuts the FY26 adjusted-EBITDA guide below the $0 breakeven floor, or shows capitation revenue declining quarter-over-quarter, removes the profitability-inflection leg that is the entire reason to own the name.
• Watch items: a quantified cybersecurity remediation charge, or a dilutive equity raise against the thin $30.3M cash balance.

Correlation Notes

• Despite the "health-managed-care" tag, TOI trades idiosyncratically. It is a value-based oncology-services operator rather than a drug developer, so correlation to biotech baskets (XBI/IBB) is low the earlier biotech-precision-therapeutics classification was simply wrong.
• The real macro sensitivity is Medicare Advantage reimbursement and CMS rate policy: Humana, Elevance and CarePlus are the counterparties, and MA-rate headlines feed directly into the capitation model's margins.
• As a sub-$500M micro-cap with an active short base, the name carries small-cap beta (IWM) during risk-off liquidity stress, though the 2026 move has been driven by company-specific turnaround and insider flow rather than index direction.
• The short overlay means price can move on covering and retail flow with no fundamental input; treat sharp green days on no news as flow, not information.